Lion's Dental Supply & Equipment

Quality Dental Operatory Equipment, Autoclaves & Supplies...All at the Lowest Prices !!                      
White Back Ground
Face Masks
Surgical Disposable Face Masks
SureSeal ASTM Level 3 Fog Free Double Chin Masks
SureSeal ASTM Level 3 Black Surgical Face Masks
SureSeal ASTM Level 2 Surgical Face Masks
SureSeal ASTM Level 1 Surgical Face Masks
Extra Safe Fog Free ASTM Level 3 Surgical Masks
Omega ASTM Level 2 Light Blue Surgical Face Masks
Halyard 47577 ASTM Level 1 Procedure Mask
Cranberry Carbon 4 Ply Black ASTM Level 3 Masks
Crosstex IsoFluid Resistant Earloop Face Mask
Defend Level 3 Earloop Face Masks
Earloop Triple Layer Filtration Face Masks
N95 Medical Particulate Respirator Face Masks
Colored KN95 Particulate Respirator Masks
3M 9502V+ KN95 Medical Particulate Respirator Mask
3M 9542V+ KN95 Medical Particulate Respirator Mask
3M 9502+ KN95 Medical Particulate Respirator Mask
3M 9501+ KN95 Medical Particulate Respirator Mask
3M 9010 N95 Particulate Respirator CDC Approved
3M 9210+ N95 Particulate Respirator CDC Approved
ProGear N95 Surgical Particulate Respirator
Honeywell DC365N95HC Surgical N95 Respirators
3M 8210V N95 Niosh Approved Particulate Respirator
3M 8210 N95 Niosh Approved Particulate Respirator
3M 8511 N95 Niosh Approved Particulate Respirator
3M 1860 N95 Niosh Approved Particulate Respirators
3M 1870+N95 Niosh Approved Particulate Respirators
Marcio KN95 Medical Particulate Respirator Mask
MakRite Medical N95 Particulate Respirator Masks
Moldex 2200N95 Series Particulate Respirator
Moldex 2300N95 Series Respirator Masks
HDX H950 N95 Particulate Respirator Masks
SAS 8610 Medical N95 Particulate Respirator Masks
UniAir N95 Medical Particulate Respirator Mask
Medical Full Face Shields for Covid-19 Protection
Air Abrasion System- Dental
Air Compressors-Dental
Air Polishers & Scalers
Apex Locators
Autoclaves & Sterilizers
Bleaching Dental Light Systems
Chairs Operatory
Curing Light Units- Halogen & Led
Delivery Units & Mobile Carts
Digital X-Ray Sensors
Electrosurgery Units For Dental
Endodontic Rotary Systems
Endodontic Obturation & Thermal Condensors
Film Processors
Implant Motor Systems
Intraoral Cameras
Laboratory Equipment
Laboratory Micro Motors
Mobile Carts
Operatory Lights
Operatory Packages
Phosphor Plate Scanner Digital X-Ray System
Piezo Scalers
Portable Delivery Units
Ultrasonic Cleaners
Ultrasonic Scalers
Vacuum Systems
X-Ray Equipment
X Ray Units
terms and conditions
Leasing And Financing
Shows & Conventions
Career opportunities

3M 9542V+ KN95 Particulate Respirator Masks With Valve

As there is a world wide shortage of Disposable Surgical Medical Face Masks Because of the CoronaVirus. These are Special Order and there are no returns. The sale of this item is subject to regulation by the U.S. FDA and therefore is Non Returnable. Once the Order is Placed we can not Cancel the Order as it goes to the Warehouse that ships the product out as fast as possible to Help those in Need.

We have all these Face Masks in Stock and Ready to ship. 1 to 5 Days Delivery Time.

3M 9542V+ KN95 Medical N95 Particulate Respirator Masks With Valve

3M 9542V+ KN95 Particulate Respirator Masks With Valve

The 3M 9542V+ Particulate Respirators are authorized for emergency use by healthcare personal during the COVID-19 public health emergency from the CDC and FDA. The 3M 9542V+ Particulate Respirators is a disposable particulate respirator that is designed to help provide reliable respiratory protection of at least 95 percent filtration efficiency against particles. This respirator can also help reduce inhalation exposures to certain biological particles (examples: mold, Bacillus anthracis, Mycobacterium tuberculosis), but cannot eliminate the risk of contracting infection, illness, or disease. Soft inner material provides added comfort while the cup shape design makes the respirator spacious and durable. Adjustable M noseclip helps provide a custom and secure seal. The respirator incorporates 3M proprietary technology with advanced electrostatically charged microfiber filter media designed for ease of breathing. This respirator is compatible with a variety of protective eyewear and hearing protection. These are Individually Wrapped. Come in Boxes of 20.

-Non-woven fabric & Knitted Headband
-Carbon Filter for smell
-Adjustable Noseclip
-Soft and Breathable
-Vertical folding design, lightweight structure
-Efficient protection
-KN95 are the same as N95 In performance.
-With Valve to keep you cool during summer
-The Valve really Cools you down a lot.

-FDA & CDC Authorized the use of 3M 9542V KN95 Respirators for emergency use by healthcare personal during the COVID-19 public health emergency.

Reg $ 37.99  Sold Out


SAS 8610 N95 Masks In Stock

3M 9542V+ KN95 Medical N95 Particulate Respirator Masks 20 Pk Sold Out  

3M 9542V+ KN95 Medical N95 Particulate Respirator Masks 40 Pk Sold Out  

3M 9542V+ KN95 Medical N95 Particulate Respirator Masks 80 Pk Sold Out  


3M Respirators in International Packaging Made Available in US during COVID-19
3M is continuing to address the COVID-19 pandemic with many tactics to help protect those responding to the outbreak, including healthcare workers and first responders. In early April, 3M reached agreement with the U.S. government on a plan that, with the Trump Administration’s assistance, will enable FEMA to import 166.5 million respirators into the United States over a 3-month period starting in April, from our plants in Asia.

3M Respirators in International Packaging Made Available in US during COVID-19 (PDF, 96.38 KB)

Respirators from Asia Imported and Distributed by FEMA (PDF, 115.88 KB)

3M Filtering Facepiece Respirators Imported to U.S. from Asia by FEMA (PDF, 546.30 KB)

3M™ Particulate Respirator 9542V User Instructions (PDF, 255.61 KB)

Non-NIOSH Approved Respirators
Emergency User Authorization (EUA) End User Information
The following 3M respirators are listed in Appendix A of the April 3rd, 2020 EUA title imported, “Non-NIOSH-Approved Disposable
Filtering Facepiece Respirators Manufactured in China”. Users should read the information below for their model before use. Please
note these are also listed at
9552/9552V, 9502, 9542, 9542V
9501, 9501+/9501V+, 9505+, 9541, 9541V
• 9502+/9502V+
• 8822 (AU), 8822 (K)

On April 3, 2020, the FDA issued an umbrella EUA for certain filtering face-piece respirators (FFRs) that are manufactured in China and are not approved by the National Institutes of Occupational Safety and Health (NIOSH). As mentioned in CDC's strategies for optimizing respirator supply, other countries approve respirators according to country-specific standards. These devices are evaluated using methods similar to those used by NIOSH and are still expected to provide adequate protection for healthcare personnel. Non-NIOSH-approved FFRs manufactured in China that have been confirmed by FDA to meet the criteria under the EUA are included below in Appendix A. Additionally, the FDA, in collaboration with CDC NIOSH, is increasing surveillance and sampling of all respirators imported from China - all respirator shipments from China that come into the U.S. will be subject to random sampling and testing by CDC NIOSH to determine whether the respirator meets the expected particulate filtration standards.

A New Generation of Vaccines Is Coming,
Some With No Needles

The coronavirus outbreak made household names of companies like Moderna Inc. and BioNTech SE, whose shots offered hope for ending the pandemic. Now a new wave of vaccines is on the horizon that may get the world over the finish line of inoculation.
Protecting 7.7 billion people is a herculean task. There are more than 250 vaccine candidates in the wings to take on the challenge, including 82 in human studies. In addition to sheer numbers, they offer unique benefits compared to the dozen now available.
The next generation includes shots built from the coronavirus’s genetic material and nasal sprays that defend without using a needle at all. They are stealthy, faster to make and easier to ship, offering workarounds for hurdles that limit the impact of the first inoculations to reach the market.
“It’s absolutely essential to share vaccine products with the entire world as quickly as possible,” said Richard Hatchett, chief executive officer of the Coalition for Epidemic Preparedness Innovations, which accelerates development of vaccines, including those against Covid-19. “The virus will have less opportunity to evolve, and it will slow down the rates of mutation that we’re seeing.”
Here’s what you need to know about the next wave of vaccines:

One-Shot Wonders
With most Covid vaccines requiring two shots, those that need only one will simplify the process. This approach is known as viral vector technology. It uses an unrelated virus, one that’s been modified so it doesn’t cause infection, to insert the directions for making the coronavirus’ spike protein into healthy cells. Those cells then crank out large amounts of the spike protein, triggering an immune response. Of the dozen candidates in human studies, most involve one injection.
With one shot, they're faster and stronger—though boosters may be needed
May be easier to update for new strains, since different genetic sequences can be delivered via the same viral vector
Can be kept refrigerated for up to two years.
People can be immune to the vector, which is often an adenovirus - a frequent cause of the common cold
All that spike protein production can trigger an immune response that can result in stronger side effects
Current use in other vaccines

Ebola vaccines use viral vector technology; scientists are evaluating it against Zika, influenza and HIV.
Companies involved

CanSino Biologics Inc, Johnson & Johnson, Gamaleya Research Institute/Russia’s Health Ministry
Current stage

Phase I
Phase II
Phase III

Response Trigger
The most common type of vaccine now in human trials—accounting for nearly one-third of those in development—protein subunit shots use a fragment of the virus to generate an immune response. It’s usually the famed spike protein that dots the surface of the coronavirus, combined with a chemical known as an adjuvant to deepen the reaction.
A mature technology that makes a stable shot
No risk of infection because they don't use live virus
Easier and less expensive to manufacture, with plenty of capacity already in the system
Finding the right protein segment can take time
The immune system may not recognize the protein fragments as a serious threat, and generate a weaker response
Booster shots may be necessary
Production of adjuvants has slowed due to bottlenecks amid surging demand
Current use in other vaccines

Subunit vaccines are used to prevent hepatitis B, whopping cough and pneumococcal pneumonia
Companies involved

Novavax Inc., Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences, Clover Biopharmaceuticals Inc./GSK/Dynavax, COVAXX/United Biomedical Inc.
Current stage

Phase I
Phase II
Phase III

Virus Decoy
These vaccines contain a coronavirus decoy—a protein shell whose shape closely mimics the virus without any of its genetic material. The so-called virus-like particle is still able to generate an immune response against the real thing.
They have the structure and form of the virus to stimulate a strong immune response without any risk of infection
Safe for people with weakened immune responses
Potentially be better at dealing with mutations
It’s difficult to make high quality, stable decoy particles in large quantities
Manufacturing costs are high
The origin and composition of the outside of the Covid virus is complex, making mimicry difficult
Current use in other vaccines

This approach is used to prevent cancer-causing human papillomavirus (HPV) infection, hepatitis B and malaria
Companies involved

Medicago Inc., VBI Vaccines Inc., Serum Institute of India/Accelagen Pty/SpyBiotech
Current stage

Phase I
Phase II
Phase III

DNA Building Block
Like the breakthrough mRNA vaccines from Pfizer Inc., BioNTech and Moderna, DNA vaccines insert a bit of genetic code into a human cell. The cell becomes a factory, producing the coronavirus spike protein to elicit an immune response. The DNA vaccines have to take an extra step, though. They must convert the genetic material into mRNA, which contains directions for making the proteins. Should a vaccine using this approach get to the market, it would be the first of its kind.
Can mobilize the immune system to slay virus-infected cells in addition to creating antibodies to prevent a viral attack
May be cheaper to make than protein-based vaccines and more stable than mRNA shots
Ideal for people with compromised immune systems.
Immune response may be weaker and the vaccine less effective
Some need to be used with a “gene gun” to push the genetic material into the cells with electric pulses, an additional logistical challenge during mass inoculation efforts
Current use in other vaccines

Companies involved

Zydus Cadila, AnGes/Takara Bio/Osaka University, Inovio Pharmaceuticals/International Vaccine Institute/Advaccine Biopharmaceutical Co.
Current stage

Phase I
Phase II
Phase III

Nasal Spray
Getting vaccinated doesn’t always require an injection. Some immunizations can be sprayed into the nose, where the virus often first takes hold. Several types, including the viral vector and virus-like particle approaches, can be given as a nasal spray.
May provide better protection against the virus given it typically infects through the respiratory tract
Avoids needles
Easier to administer than shots that require freezing temperatures and preparation by medical staff
May cause more severe side effects
Their use and potency may be limited in certain age groups
Current use in other vaccines

Nasal sprays are widely used as alternative to flu shots
Companies involved

Codagenix/Serum Institute of India, Hong Kong University/Xiamen University/Beijing Wantai Biological Pharmacy
Current stage

Phase I
Phase II
Phase III

Coronavirus Medley
SARS-CoV-2 is mutating, and there is concern that the current raft of shots may not provide immunity against those variants. But some vaccines are now simultaneously targeting several strains. There are also combination shots designed to protect against Covid and seasonal influenza. While research is at an early stage, these vaccines could be the ultimate answer to the constantly mutating coronavirus, so regulators may fast-track such shots if they’re modified versions of already-approved vaccines
Protect against a wide range of viral variants, reducing the hassle of having to vaccinate repeatedly
Coverage for multiple infections with one shot, reducing the burden on patients and health systems
Relatively unproven technology, and it's still unknown if multivalent shots can be successfully created against coronavirus strains
Difficult to pinpoint which component could be the cause of any side effects in combination vaccines
Current use in other vaccines

Influenza vaccines contain multiple strains; childhood vaccines are given in combinations that cover several pathogens
Companies involved

With combination immunizations:

Novavax Inc., Vaxess Technologies/Medigen Vaccine Biologics, Vivaldi Biosciences
With multivalent vaccine:

Moderna, Clover Biopharmaceuticals Inc.
Current stage

Phase I
Phase II
Phase III

Dental Equipment From Lions Dental Supply